SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - SurModics reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and compared to break-even earnings per share a year ago, representing an earnings surprise of 50% [1] - The company posted revenues of $29.92 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 10.55%, and down from $30.55 million year-over-year [2] - SurModics has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] Stock Outlook - SurModics shares have declined approximately 9.7% since the beginning of the year, while the S&P 500 has gained 2.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.04 on revenues of $34.65 million, and $0.19 on revenues of $142.88 million for the current fiscal year [7] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 48% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]